Dictionary

allow_url_fopen is ENABLED Dictionary Search

vasomotor

Synonyms

Adjective

1. constriction

2. dilation, dilatation

Usage
Unmet Needs in Vasomotor Symptoms in African American Women and the Road Ahead - Patient Care Online
Vasomotor Rhinitis: Current Concepts and Emerging Therapies - Cureus
New Non-Hormonal Menopause Drug Backed by NICE - Medscape
EU approval for new hormone-free treatment option for vasomotor symptoms associated with menopause or caused by endocrine therapy for breast cancer - Bayer
Lynkuet® (elinzanetant) for the Treatment of Vasomotor Symptoms Due to Menopause - MPR - Medical Professionals Reference
FDA Approves Elinzanetant as First Nonhormonal Therapy for Menopause Vasomotor Symptoms - Pharmacy Times
Hormone Therapy Does Not Increase Cardiovascular Disease Risk in Younger Postmenopausal Women - Northwestern University
Midlife insulin levels influence timing and duration of menopausal vasomotor symptoms - News-Medical
Elinzanetant for Vasomotor Symptoms From Endocrine Therapy for Breast Cancer - The ASCO Post
How African American Patients Are Affected By Vasomotor Symptoms - Patient Care Online
How African American Patients Are Affected By Vasomotor Symptoms - Contemporary OB/GYN
Estetrol Improves Vasomotor Symptoms With No BP Effects - Medscape
Managing Vasomotor Symptoms: Understanding the Menopause Transition and Treatment Options - Pharmacy Times
Special Report: Managing vasomotor symptoms in menopause - Contemporary OB/GYN
Pathophysiology of Vasomotor Symptoms in Menopause - Patient Care Online
Fezolinetant shows significant real-world improvements in vasomotor symptoms, sleep - Contemporary OB/GYN
NK Receptor Antagonism as Therapeutic Strategy for Vasomotor Symptoms - Contemporary OB/GYN
FDA approves elinzanetant (Lynkuet) for vasomotor menopausal symptoms - Contemporary OB/GYN
Pooled Safety Analysis Supports Elinzanetant for Vasomotor Symptoms Through 52 Weeks - Patient Care Online
Elinzanetant Demonstrates Rapid and Sustained Efficacy in Reducing Vasomotor Symptoms Across OASIS Clinical Trials - Pharmacy Times
Elinzanetant Reduces Postmenopausal Sleep Disturbances Independent of Improvements in Vasomotor Symptoms - Medscape
Vasomotor Symptoms Are Linked to Vascular and Cartilage Structural Changes in Postmenopausal Women - Wiley
U.S. approval of a new hormone-free treatment option for moderate to severe vasomotor symptoms due to menopause - Bayer
FDA extends review period for Bayer's elinzanetant for vasomotor symptoms - Contemporary OB/GYN
Impact of Vasomotor Symptoms on Patient Quality of Life - Patient Care Online
Noema Pharma Announces Phase 2a Study Results with - GlobeNewswire
Elinzanetant Shows Strong 52-Week Safety for Vasomotor Symptoms: James Simon, MD - The American Journal of Managed Care® (AJMC®)
New Research on Hormone-Free Hot Flash Treatments - Breast Cancer.org
Special Report: How neurokinin receptor antagonists are reshaping the VMS treatment landscape - Contemporary OB/GYN
Elinzanetant Eases Vasomotor Symptoms in HR+ Breast Cancer - Docwire News
Acta Obstetricia et Gynecologica Scandinavica | NFOG Women's Health Journal | Wiley Online Library - Wiley
Four Studies Build Evidence for Elinzanetant as a Safe, Effective Nonhormonal Option for Menopausal Vasomotor Symptoms - Patient Care Online
Elinzanetant significantly reduces frequency of moderate to severe vasomotor symptoms associated with endocrine therapy for breast cancer in Phase III OASIS-4 study - Bayer
Bayer receives FDA approval for non-hormonal menopause therapy - BioPharma Dive
New nonhormonal therapies transform hot flash treatment in menopause - Contemporary OB/GYN
VisualAbstract: Elinzanetant Effectively Reduces Vasomotor Symptoms from Endocrine Therapy for Breast Cancer - 2 Minute Medicine
How New Pathways Are Easing Vasomotor Symptoms in Breast Cancer Care - Contemporary OB/GYN
Special Report: Recent advancements in pharmacologic and nonpharmacologic treatment options - Contemporary OB/GYN
Navigating Vasomotor Symptoms From Endocrine Therapy in Breast Cancer Treatment - Contemporary OB/GYN
Elinzanetant recommended for approval in EU as treatment of moderate to severe vasomotor symptoms - Bayer
Dr Cardoso on the Effect of Elinzanetant on Vasomotor Symptoms in HR+ Breast Cancer - OncLive
New menopause drug to target hot flashes without hormones gets FDA approval - ABC7 New York
FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause - The American Journal of Managed Care® (AJMC®)
New Data Show Elinzanetant Is a Safe, Well-Tolerated Nonhormonal Therapy for Menopausal Vasomotor Symptoms - Pharmacy Times
Nitroglycerin withdrawal increases endothelium-dependent vasomotor response to acetylcholine - JACC Journals
Managing Vasomotor Symptoms of Menopause: A Topline Comparison of Treatments - Patient Care Online
FDA Green-Lights Elinzanetant, First Dual NK-1/NK-3 Antagonist, for Moderate to Severe Vasomotor Symptoms of Menopause - Patient Care Online
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause - BioSpace
Elinzanetant Demonstrates Clinically Meaningful Reductions in Menopausal Vasomotor Symptoms, Meta-analysis Shows - Patient Care Online
Menopause drug reduces hot flashes by more than 70%, international clinical trial finds - Medical Xpress
Vasomotor Symptoms of Menopause: Facts At-a-Glance for Primary Care - Patient Care Online
OASIS-4 Trial: Elinzanetant Reduces Frequency of Vasomotor Symptoms Related to Endocrine Therapy for HR-Positive Breast Cancer - Patient Care Online
Novel Nonhormonal Drug Approved for Menopause Hot Flashes - MedPage Today
Phase III OASIS-4 Trial Shows Elinzanetant Significantly Reduces Endocrine Therapy–Related Vasomotor Symptoms in Patients with HR-Positive Breast Cancer - Applied Clinical Trials Online
Elinzanetant reduces vasomotor symptoms during breast cancer endocrine therapy - medwirenews.com
Narcolepsy Patients Show Enhanced Brain Waste Clearance Through Compensatory Vasomotor Activity - Sleep Review
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause - Yahoo Finance
Many physicians still consider VMS to be transient and inconsequential, but new research suggests otherwise—are you all caught up? - MDLinx
Plant-Based Estrogen Diminished Menopause Symptoms - MedPage Today
Preexisting Chronic Pain Tied to Menopausal Symptom Burden - Medscape
OASIS-4 trial: Efficacy and safety of elinzanetant for vasomotor symptoms associated with adjuvant endocrine therapy in women with breast cancer - European Medical Journal
How a Mediterranean diet helps women manage menopausal symptoms - News-Medical
newsGP - Vasomotor symptoms key to perimenopause diagnosis - Royal Australian College of General Practitioners (RACGP)
Study: Elinzanetant cuts vasomotor symptoms in women with breast cancer on endocrine therapy - Medical Xpress
Where Menopause Hits Hardest - HealthCentral
MHRA Approves Nonhormonal Drug for Menopausal Hot Flushes - Medscape
Heart Risks of Hormone Therapy for Hot Flashes Double Starting at This Age - MedPage Today
Nonhormonal therapies transform menopause care in 2025 - Contemporary OB/GYN
With FDA nod, Bayer's Lynkuet enters US market for nonhormonal menopause symptom meds - Fierce Pharma
MHRA approves elinzanetant to treat moderate to severe vasomotor symptoms (hot flushes) caused by menopause - GOV.UK
Bioadhesive and conformable bioelectronic interfaces for vasomotoricity monitoring and regulation - Nature
A profile of safety and efficacy of fezolinetant for the treatment of menopausal vasomotor symptoms. - Physician's Weekly
You know VMS is underdiagnosed. But are you part of the problem? - MDLinx
FDA Extends Review Period for Bayer’s Elinzanetant for Moderate to Severe Menopausal Symptoms - Pharmaceutical Executive
Hormone Therapy for Menopause: Timing, Safety, and Best Candidates - The American Journal of Managed Care® (AJMC®)
‘Ignoring hot flushes is wrong’: study challenges assumptions about perimenopause symptoms - The Guardian
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms - Yahoo Finance
Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer - University College Dublin
Abcellera gains Canadian clearance for phase I study of ABCL-635 for vasomotor symptoms in menopause - BioWorld MedTech
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause - BioSpace
Bayer Receives First Global Approval for Lynkuet to Treat Menopause Vasomotor Symptoms - Femtech Insider
Study finds insulin, not just BMI, drives key menopause symptom patterns - Benefits and Pensions Monitor
UVic research brings hope to women with premenopausal hot flashes - Victoria News
Magnitude of placebo response in clinical trials of paroxetine for vasomotor symptoms: a meta-analysis - Frontiers
FDA accepts elinzanetant NDA for vasomotor symptoms in menopause - Contemporary OB/GYN
Bayer Elinzanetant recommended for nod in EU for moderate to severe vasomotor symptoms - Medical Dialogues
New study may offer hope to women with hot flashes, night sweats - UVic News
FDA approves Lynkuet for moderate to severe hot flashes due to menopause - Healio
Elinzanetant Excels in Phase 3 Study for Vasomotor Symptom Relief - The American Journal of Managed Care® (AJMC®)
Review: Nonhormone Therapies for Menopausal Hot Flashes - Cleveland Clinic
Bayer receives first approval for Lynkuet in UK as treatment for vasomotor symptoms associated with menopause - Indian Pharma Post
Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms - The Lancet
Best nonhormone methods for managing vasomotor symptoms - Contemporary OB/GYN
Nonpharmacologic Options Can Help Manage Vasomotor Symptoms of Menopause - Medscape
Menopausal Vasomotor Symptoms and White Matter Hyperintensities in Midlife Women - Neurology® Journals
Bayer gets UK nod for Lynkuet for moderate to severe vasomotor symptoms associated with menopause - Medical Dialogues
Vasomotor symptom frequency linked to diabetes risk - Contemporary OB/GYN
Fezolinetant significantly reduces vasomotor symptoms in post-menopausal women - 2 Minute Medicine
2023 Menopause Society Annual Meeting Highlights Vasomotor Symptoms Treatment - Endocrinology Advisor
Elinzanetant Significantly Improves Vasomotor Symptoms - Medscape
Foreign Language Equivalents
Foreign Language Equivalents of 'vasomotor'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
vasomtoor,   vasomotro,   vasomotpr,   vasomoter,   vsaomotor,   vaosmotor,   vasomotot,   basomotor,   vasomtor,   vaso,otor,   vassomotor,   casomotor,   vaaomotor,   vvasomotor,   vssomotor,   vasootor,   vasoomtor,   vasoomotor,   vasomottor,   asomotor,   vasomoto,   avsomotor,   vasomptor,   vasomoor,   vasomotoe,   vasmotor,   vasomotr,   vasomoyor,   vaomotor,   vasomotorr,   vasmootor,   vaasomotor,   vasomootr,   vadomotor,   vaspmotor,   vasimotor,   vsomotor,   vasomotoor,   vasomootor,   vasomitor,   vasomotir,   vasonotor,   vasommotor,   vasomoror
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z